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The largest single underlying cause of hepatocellular carcinoma (HCC) worldwide is hepatitis B virus (HBV) infection. Hepatitis B virus
increases cellular oxidative stress and the development of HCC occurs after a long latency period. The study was carried out to
determine whether mitochondrial DNA abnormalities were associated with HCC in individuals with HBV. The frequency of mutation
and deletion of specific areas of the mitochondrial genome in tumour and matched normal tissue of patients with HBV infection was
investigated in the current study. The percentage of control subjects harbouring D-loop mutations was 11%, which was significantly
lower than that observed in both the noncancerous (49%, P¼ 0.033) and tumour tissue (59%, P¼ 0.014) of patients with HCC. In
contrast, the number of cases in which the common 4977 bp deletion of the mitochondrial genome was detected was significantly
greater in control liver and noncancerous liver tissue of subjects with HCC (100 and 95%, respectively) than in cancerous liver tissue
(28%, Po0.001). These observations suggest that the inflammatory process contributes to the rate of mitochondrial mutations.
However, the lower frequency of the large deletion in cancerous tissue suggests that there is selection against either mitochondria,
which harbour large deletions, or against cells that contain these mitochondria during hepatocarcinogenesis.
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Hepatocellular carcinoma (HCC) is the fifth most frequent cancer
worldwide and is the third highest cause of cancer-related death
(Block et al, 2003). Unlike many forms of cancer, more than 95%
of HCC cases arise upon a background of persistent inflammatory
disease. Although the disease aetiologies are diverse, hepatitis B
virus (HBV) and hepatitis C virus (HCV) are implicated in the
majority of cases (Waris and Siddiqui, 2003).
Chronic infection with either HBV or HCV results in the
production of reactive oxygen species (ROS) in the liver, leading to
an increase in potentially mutagenic DNA lesions (Waris and
Siddiqui, 2003). Mitochondrial DNA is more susceptible to
sustained DNA damage compared with nuclear DNA due to the
lack of histones and decreased capacity for DNA repair (Kang and
Hamasaki, 2002). While genomic DNA is complex, the human
mitochondrial genome is only 16.5 kb in length, encoding 13
polypeptides of the respiratory chain, 22 transfer RNAs and two
rRNAs (Taanman, 1999). The displacement loop (D-loop) region is
the major control site for mtDNA expression containing the origin
of replication for the heavy DNA strand and the major promoters
of transcription (Taanman, 1999). Mutations within the D-loop
region have been detected in a variety of cancers including
oesophageal (Miyazono et al, 2002), gastric (Ma´ximo et al, 1999),
thyroid (Ma´ximo et al, 2002), breast (Richard et al, 2000) and HCC
in HCV-infected individuals (Nishikawa et al, 2001).
Although various deletions of the mitochondrial genome have
been reported, the 4977 bp deletion is the most widespread and has
been associated with ageing in tissues (Kowald, 1999). While
increases in the frequency of the 4977 bp deletion have been
demonstrated in tumours, the levels in HCC of subjects with HCV
is thought to be reduced (Kotake et al, 1999).
We hypothesised that increased oxidative stress associated with
HBV infection in individuals with HCC would lead to an increased
burden of mitochondrial DNA mutation. We therefore sequenced a
small portion of the hypervariable D-loop region of mitochondria
from individuals with HCC in matching tumour and nontumour
liver tissue to determine the frequency of mitochondrial
mutations. In addition, we investigated the frequency of deletions
in noncancerous and tumour tissue to help understand the
mechanisms that lead to tumorigenesis.
MATERIALS AND METHODS
Tissue specimens
We collected 124 liver specimens from 62 ethnic Chinese patients
who underwent surgery at the Department of Surgery, Chinese
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University of Hong Kong. These included 59 HCC and correspond-
ing noncancerous but cirrhotic tissue from individuals with
chronic HBV, and an additional three paired samples from
individuals with HCV and HCC. In addition, we obtained a further
nine control samples of normal liver from patients undergoing
partial hepatic resection with diseases other than HCC, usually
colorectal metastases. All samples were obtained with appropriate
local ethical committee approval and informed consent was
obtained from recruited patients.
Analysis of mutations
DNA was extracted from tissue samples by the QiaAmp DNA
micro kit (Qiagen, USA). Each DNA sample (100 ng) underwent
PCR amplification with specific primers designed using the Primer
3 program (Rozen and Skaletzky, 1996) to amplify a 334 bp region
of the D-loop (forward primer: 50-gagctctccatgcatttggt-30; reverse
primer: 50-tctttgtttttggggtttgg-30). Cycle conditions were as follows:
an initial denaturation step of 941C for 5 min; two cycles of 941C
for 45 s, 641C for 1 min 15 s, 701C for 30 s; 35 cycles of 941C for 45 s,
581C for 1 min 15 s, 701C for 30 s; final extension step of 701C for
10 min. Sequencing was performed with an ABI 377 gel-based
sequencing machine after labelling with the BigDye terminator
cycle sequencing kit 3.1 on a GeneAmp PCR system 9700 (Applied
Biosystems, Foster City, CA, USA), using the same PCR primers.
Analysis of the common deletion
The method employed was essentially similar to that described
previously (Ma´ximo et al, 2002), using the internal primers
(MITIN: forward, 50-ctgagccttttaccactccag-30, reverse 50-ggtgattga-
tactcctgatgcg-30) and external primers spanning the deleted
fragment (MITOUT: forward 50-cccaactaaatactaccgtatgg-30, reverse
50-ggctcaggcgtttgtgtatgat-30) as described (Ma´ximo et al, 1999).
Cycle conditions were as follows: an initial denaturation step of
951C for 15 min; 40 cycles of 941C for 30 s, 581C for 30 s, 721C for
30 s; final extension at 721C for 2 min. Products were resolved on a
1.6% agarose gel, stained with ethidium bromide and visualised
under UV illumination.
Statistics
The frequency of mutations and deletions in samples were
analysed by nonparametric Mann–Whitney U-test. Associations
between the presence of either gene deletion or mutations and
clinicopathological markers of tumour behaviour such as capsular
invasion and tumour stage were studied by univariate analysis and
by multivariate analysis using a Cox proportional hazards model
in which a time constant was set and where either the presence of
gene deletion or mutation in the tumour was set as the event.
Statistical analysis was performed using SPSS 12.0, Chicago, IL,
USA).
RESULTS
Patient characteristics
The clinical characteristics of the 62 patients composing the study
group are given in Table 1. The majority were male and infected
with HBV. Only six of the patients had normal underlying
nontumour liver tissue, the remainder had either fibrosis or
cirrhosis. Four patients had major vascular invasion by tumour
and a further eight patients had microvascular invasion. There
were no statistical associations between the presence of either
mitochondrial D-loop deletions or mutations and the clinico-
pathological features of aggressiveness of the HCCs examined.
PCR and sequencing
For mutation analysis, we successfully sequenced DNA from 61 of
the 62 sample pairs of cancerous and noncancerous liver tissue,
and all control samples (Figure 1D shows a representative gel). For
deletion analysis, all 62 sample pairs and all controls were
successfully analysed. The presence of the 4977 bp deletion was
determined by the presence of a 214 bp band (Figure 2B).
Routinely using the MITOUT primers, a faint nonspecific band
could be detected in both positive and negative samples. After
sequencing, this was found to be a unidirectional PCR product
from the forward primer, terminating outside the deleted region
and was also used as an additional internal PCR control. In
addition, both specific products from the MITIN and MITOUT
PCRs were sequenced to validate the assay.
Mutations increase in both cancerous and noncancerous
liver tissue of patients with HBV
Comparison of mutations was performed against an mtDNA
sequence, Genbank (accession no. JO1415). All samples contained
a T-C transition at nucleotide 489, a C insertion between 311 and
312 and all but one sample pair exhibited a G-A transition at
nucleotide 263. These have been reported elsewhere as poly-
morphisms (Andres et al, 1999) and were not included in
subsequent analysis. The frequency of subjects harbouring D-loop
mutation, which is summarised in Figure 1, was significantly
greater in the liver tissue of subjects with HCC compared with
normal control cases (59 vs 11%, P¼ 0.014), and noncancerous
tissue of patients with HCC compared with control tissue (49 vs
11%, P¼ 0.033). On the whole, the same mutations (if present)
observed in noncancerous tissue were also present in tumour
Table 1 Characteristics of patients with HCC and their tumours
Number/median (range) Percentage
Age (years) 55 (32–78)
Gender
Male 55 (89%)
HBV 58 (94%)
HCV 5 (8%)
Nontumour liver tissue
Normal 6 (10%)
Fibrosis 19 (31%)
Cirrhosis 37 (60%)
AJCC tumour stage
1 2 (3%)
2 39 (63%)
3 15 (24%)
4 6 (10%)
Tumour maximum size (cm) 3.5 (1.6–11.9)
Capsular invasion
Y 34 (50%)
N 18 (29%)
No capsule 10 (21%)
Microvascular invasion
Y 8 (13%)
N 54 (87%)
Serum alpha fetoprotein (U/l) 96 (2–699 800)
HCC¼ hepatocellular carcinoma; HBV¼ hepatitis B virus; HCV¼ hepatitis B virus.
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tissue from the same individual, although additional mutations
were observed in some of the tumour samples. However, there was
no significant increase in the frequency of mutation in liver
tumour tissue compared to paired noncancerous liver tissue from
the same patient (P¼ 0.41).
Frequency of mtDNA deletion is reduced in cancerous
tissue
In contrast to the results obtained for mtDNA mutations, the
prevalence of deletion was significantly lower in HCC tissue
compared to noncancerous tissue (28 vs 95%; Po0.001). The
frequency of deletion within control normal liver tissue was similar
to that obtained for noncancerous liver tissue of patients with HCC
(100 vs 95%) (Figure 2).
DISCUSSION
We have demonstrated that mitochondrial DNA abnormalities are
common in the D-loop of patients with HCC upon a background of
HBV. The D-loop region is a major control site for mtDNA
replication containing the leading origin of replication and the
major promoters required for transcription. HBV infection, in
terms of patient numbers, is a more important clinical disease
worldwide and is responsible for nearly 60% of HCC cases (Lai
et al, 2003). While mitochondrial mutations have been demon-
strated in HCC, previous studies have been carried out on
individuals with hepatitis C (Nishikawa et al, 2001; Lee et al,
2004; Kubo et al, 2003).
The 4977 bp deletion is deleterious, affecting much of complex I
of the electron transport chain, yet due to the number
of mitochondria and multiple copies of mtDNA in each
mitochondrion only 0.004% of liver mtDNA is thought to be
affected in normal individuals (Kotake et al, 1999). The
incidence of the 4977 bp deletion in liver increases with the
age of subjects (Fukushima et al, 1995) and with chronic
alcohol abuse (Mansouri et al, 1997). In our series, the mean
age was 55 years (711.5), and it is therefore not surprising
to detect the common 4977 bp deletion in 95% of the non-
cancerous tissue samples and also the control subjects. Yet, while
ageing is associated with an increased incidence of mtDNA
deletion, we found a lower prevalence of deletions in the cohort
of HCC.
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Figure 1 Frequency of mutation in the D-loop region of (A) control
tissue, (B) noncancerous liver tissue and (C) HCC tumour tissue. (D)
shows a typical gel. M: markers. Lane C shows the negative control. Lanes 1,
2 and 3 show PCR products derived from control, noncancerous and
tumour liver tissue, respectively.
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Figure 2 (A) Frequency of the 4977 bp deletion in control tissue,
noncancerous tissue and HCC liver tissue. (B) A typical gel. Lanes Ci and
Co are the negative control lanes for MITIN and MITOUT PCRs. Lanes 1
and 3 show the 142 bp PCR products derived from using the MITIN
internal control primers. Lanes 2 and 4 show the presence and absence of
the deleted band, respectively (214 bp).
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In the current study, no matched blood samples were available
to characterise unknown polymorphisms in this patient
cohort. Nevertheless, given the similaritities in the frequency
of D-loop variants observed in the current study and
those observed in previous studies, albeit on individuals with
HCC from different disease aetiologies (Nishikawa et al, 2001;
Kubo et al, 2003), indicate that these data give an accurate
representation of mutation frequency within the sequence of
mtDNA analysed.
We observed a decrease in the frequency of the common 4977 bp
mtDNA deletion in cancer compared to noncancerous liver tissue.
This is in apparent agreement with two previous studies, the first
of which demonstrated a decrease in deletion frequency between
normal, cirrhotic and tumour tissue (Kotake et al, 1999), and the
second of which indicated a decrease in the deletion level in
tumour compared to noncancerous in males but not females (Yin
et al, 2004). In our cohort of patients who had tumours containing
the deletion, all were male; however, as only seven of 62 of our
subjects were female, it would be difficult to make comparisons
between the sexes. In a third study, mtDNA deletions could not be
detected in either noncancerous or tumour tissue (Nishikawa et al,
2001); however, it is uncertain whether this is due to methodology
or if this was due to the differences in the effects of underlying
HCV to other disease aetiologies.
We observed in three tumours a deletion of the c-tract region of
the D-loop, which was not apparent in the paired noncancerous
tissue. Replication of mtDNA uses DNA polymerase g, which has a
reduced fidelity for homopolymeric sequences, making this
particular region highly susceptible to mutation and deletion
(Copeland et al, 2003). In a setting of increased cellular and thus
mitochondrial replication, there is an increased opportunity for
uncorrected errors to be introduced. This suggests that while
mitochondria containing large deletions in the encoding regions of
DNA are eliminated during transformation, small deletions around
the regulatory D-loop may provide a selective advantage. Thus,
abnormalities within mitochondrial DNA could have important
consequences in terms of mitochondrial replication, as well as
being an indicator of more widespread DNA damage in the cell.
Indeed, it has been demonstrated that mitochondria of tumour
cells selectively proliferate when tumour cells are fused with
normal cells (Polyak et al, 1998).
This is the first report to our knowledge that has made
observations on mtDNA mutations and deletions in patients with
HBV, the largest single underlying cause for HCC worldwide. The
presence of mtDNA deletions are thought to be indicative of tissue
ageing, yet in the apparently normal tissue of patients with HCC,
they exist in conjunction within mitochondria containing homo-
plasmic mutations of the D-loop. This observation of deletions in
conjunction with mutations indicates that mutation of the D-loop
occurs at a relatively early stage in HBV infection. The
development of HCC only occurs after a long latency period of
20–30 years after the initial HBV infection, and these observations
would indicate that mtDNA mutations occur independently of
neoplastic transformation. Conversely, the reduction in the
frequency of the common deletion in liver tumours indicates that
there is an active selection pressure against the presence of mtDNA
with large deletions, or more controversially that a population of
liver cells do not undergo the typical ageing response and
subsequently form the liver tumour. As yet, there is little evidence
to support these hypotheses; however, it has been shown recently
that mitochondrial DNA copy number is reduced in tumours (Lai
et al, 2003; Yin et al, 2004), possibly indicating an active selection
process during neoplasia. Yet, while mutations and deletions
appear to be relatively common in these patients and may be
related to carcinogenesis, they do not appear to be related to an
aggressive phenotype on the basis of their clinical and pathological
behaviour.
In summary, our data clearly demonstrates that mtDNA
mutations are present in a large proportion of HCC upon
a background of HBV infection, but deletions are rare. Moreover,
the observation that deletions coexist with mutations in
noncancerous but not HCC tissue may indicate that there is either
(i) a commitment to form HCC occurs at an early stage before
ageing effects are noted or (ii) a strong selection pressure
during carcinogenesis in favour of cells containing mitochondria
with no deletions. This may account for the long latency period
previously noted.
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